论文部分内容阅读
目的:探讨环磷酰胺联合人免疫球蛋白治疗系统性红斑狼疮的临床疗效及对血清白细胞介素-4(IL-4)及单核细胞趋化蛋白4(MCP-4)水平的影响。方法:选取我院2013年1月到2014年5月收治的76例系统性红斑狼疮患者进行研究,随机分为观察组和对照组各38例。对照组使用环磷酰胺联合强的松的治疗,观察组采用人免疫球蛋白、环磷酰胺及强的松联合治疗,应用系统性红斑狼疮疾病活动度评分(SLEDAI)评价疾病程度,记录治疗前后两组24h尿蛋白、血清IL-4及MCP-4水平,并观察不良反应发生率。结果:治疗后两组SLEDAI评分、24h尿蛋白及血清IL-4及MCP-4水平较治疗前均显著降低(P<0.05),且观察组均显著低于对照组(P<0.05)。观察组不良反应发生率显著低于对照组(P<0.05)。结论:环磷酰胺联合人免疫球蛋白治疗系统性红斑狼疮的效果显著,有效降低了患者血清IL-4及MCP-4的水平,对患者的预后有积极的影响。
Objective: To investigate the clinical efficacy of cyclophosphamide combined with human immunoglobulin in the treatment of systemic lupus erythematosus (SLE) and its effect on the levels of serum interleukin-4 (IL-4) and monocyte chemoattractant protein 4 (MCP-4). Methods: A total of 76 patients with systemic lupus erythematosus who were treated in our hospital from January 2013 to May 2014 were selected and randomly divided into observation group and control group, with 38 cases each. The control group was treated with cyclophosphamide combined with prednisone. The observation group was treated with human immunoglobulin, cyclophosphamide and prednisone, and the disease severity was evaluated by SLEDAI. Two groups of 24h urine protein, serum IL-4 and MCP-4 levels, and to observe the incidence of adverse reactions. Results: After treatment, the SLEDAI score, 24h urinary protein and serum IL-4 and MCP-4 levels were significantly lower than those before treatment (P <0.05), and the observation group were significantly lower than the control group (P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: The effect of cyclophosphamide combined with human immunoglobulin in the treatment of systemic lupus erythematosus is significant, which effectively reduces the level of serum IL-4 and MCP-4 in patients and has a positive effect on the prognosis of patients.